Mizuho raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $24 from $23 and keeps a Neutral rating on the shares following the “good” Q2 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Buy Rating on ACADIA Pharmaceuticals Driven by Daybue’s Sales Growth and Market Expansion
- Acadia Pharmaceuticals price target raised to $27 from $23 at BofA
- Acadia Pharmaceuticals price target raised to $38 from $37 at Citizens JMP
- ACADIA Pharmaceuticals: Strong Financial Performance and Promising Outlook Justify Buy Rating
- ACADIA Pharmaceuticals: Balanced Outlook Amid Solid Performance and Future Uncertainties